Acute Treatment vs. Maintenance: Different Goals
Ketamine therapy for depression, anxiety, and chronic pain typically unfolds in two distinct phases that require different protocols, dosing, and expectations:
Acute treatment (also called the loading phase or induction phase) aims to rapidly achieve therapeutic effect. See how often you can take troches for common scheduling frameworks — to produce a significant, meaningful reduction in symptoms within days to weeks.
Maintenance treatment aims to sustain the therapeutic benefit achieved during the acute phase, preventing relapse and maintaining the functional gains made.
Troches can serve both purposes, but the protocols, frequency, and expectations differ substantially between them. Our titration guide covers the dose-finding process that bridges these two phases.
The Acute Treatment Phase With Troches
Standard Loading Protocols
Most ketamine troche prescribers use one of several loading protocols to achieve initial antidepressant or analgesic effect:
Twice-weekly protocol: Sessions on two non-consecutive days per week (e.g., Monday and Thursday) for 4 to 6 weeks. This mirrors the structure of IV ketamine acute treatment protocols adapted for the outpatient sublingual setting.
Three-times-weekly protocol: For patients with severe symptoms or incomplete response to twice-weekly dosing. This intensive protocol typically runs for 2 to 4 weeks before reassessment.
Weekly protocol: Used when patients can tolerate a slower treatment course, have logistical constraints, or when the prescriber's clinical judgment supports a less intensive approach. Response may take longer to establish but the protocol is more sustainable.
What to Expect During Acute Treatment
During the loading phase, most patients experience a gradual but meaningful improvement in their primary symptoms:
- For depression: reduced hopelessness, improved energy, decreased ruminative thinking, improved sleep
- For anxiety: reduced worry and physiological arousal, increased willingness to engage with previously avoided situations
- For chronic pain: reduction in pain intensity, improved function
Full response typically emerges after 3 to 6 weeks of consistent treatment, though some patients notice improvement after the first or second session. Partial response by 4 to 6 weeks is an indication to reassess dose, frequency, and whether additional support (concurrent psychotherapy, medication adjustment) is needed.
Dose Range for Acute Treatment
Acute treatment doses are typically in the moderate to higher range of the prescribed spectrum, determined through individual titration. Common acute treatment doses range from 150 to 400 mg per session, with the specific dose established through the titration process described in the titration guide.
Transitioning to Maintenance
Once a patient has achieved adequate response during the acute phase — defined as meaningful symptom reduction (typically a 50% or greater improvement on clinical rating scales) that persists between sessions — the focus shifts to maintaining that improvement.
When to Transition
Indicators that a patient is ready to transition from acute to maintenance:
- Sustained improvement lasting 5 to 7 days or longer between sessions
- Reduced symptom burden that allows return to valued activities
- Patient and provider agreement that the acute phase goals have been met
- Stable social and functional status
The transition is gradual — session frequency is reduced incrementally rather than abruptly stopped.
Standard Maintenance Protocols
Weekly maintenance: The first step down from twice-weekly or three-times-weekly acute treatment. Weekly sessions maintain plasma neurobiological changes (sustained BDNF production, synaptic remodeling) without the intensity of a loading schedule.
Biweekly maintenance (every 2 weeks): The most common long-term maintenance frequency for patients who have been in remission for 3 or more months. Most patients in stable remission can sustain their improvement on biweekly sessions.
Monthly maintenance: For patients who show durable responses lasting 3 to 4 weeks between sessions. Monthly maintenance is cost-effective and minimizes the cumulative dose exposure over time.
As-needed maintenance: Some long-term patients learn to recognize early warning signs of relapse (sleep deterioration, returning rumination, increasing pain) and use a single troche session in response. This approach is less structured but may suit motivated, experienced patients who have been stable for extended periods.
Maintenance Dose
Maintenance doses are often lower than acute treatment doses — sometimes by 25 to 50 percent. After the neuroplasticity "priming" effect of the acute treatment phase, smaller doses are often sufficient to maintain the therapeutic signal. Many providers deliberately keep maintenance doses conservative to minimize cumulative exposure and reduce the risk of adverse effects or tolerance development.
How Long Does Maintenance Last?
This is one of the most common questions patients ask, and the answer is genuinely individualized:
- Short-term maintenance: Some patients with situational depression or a single episode achieve lasting remission after a 3 to 6 month course and successfully discontinue ketamine.
- Long-term maintenance: Patients with chronic treatment-resistant depression, chronic pain, or recurring conditions may require indefinite maintenance to prevent relapse.
- Time-limited trials off ketamine: Most providers recommend periodic trials of lower frequency or cessation (with close monitoring) to assess whether ketamine is still needed.
The trajectory for most patients is gradual reduction in frequency over 6 to 18 months if they remain stable, with reinduction if relapse occurs.
Response Durability: What Determines How Long Benefit Lasts
Not all patients maintain improvement equally well between sessions. Factors that affect response durability:
Concurrent antidepressant therapy: Patients maintained on oral antidepressants during ketamine treatment often show longer-lasting responses than those on ketamine alone. The antidepressant may help sustain the neuroplastic changes that ketamine initiates.
Psychotherapy: Integration therapy and ongoing psychotherapy are associated with more durable ketamine responses. Without psychological work to consolidate insights and behavior changes, the neurobiological window opened by ketamine may not be fully utilized.
Lifestyle factors: Sleep quality, physical activity, and social connection all modulate response durability. Patients who make lifestyle changes during ketamine treatment maintain responses longer.
Underlying diagnosis: TRD associated with specific biological vulnerabilities (e.g., high inflammatory markers, genetic factors) may relapse more quickly than depression with clearer psychosocial precipitants.
Tapering and Discontinuation
When transitioning off ketamine (after a stable period or by mutual decision with the provider), the process should be gradual:
- Reduce session frequency progressively (not all at once)
- Monitor symptom scores closely during each frequency reduction
- Have a clear plan for reinduction if symptoms return
- Continue psychotherapy and other supportive treatments during the taper
Abrupt discontinuation after long-term maintenance can produce a relapse of depressive or pain symptoms — not a withdrawal syndrome per se, but a loss of therapeutic effect without the gradual transition that allows other treatments to compensate.
Distinguishing Response from Dependency
An important distinction patients and providers must navigate: the difference between maintaining a medically necessary treatment that prevents relapse (appropriate maintenance) and psychological or pharmacological dependency (a problem).
Signs that maintenance therapy is clinically appropriate:
- Sessions produce consistent therapeutic benefit
- Symptom ratings improve measurably after sessions
- Functional outcomes (relationships, work, activities) remain improved
- Dose is stable or decreasing, not escalating
Signs that warrant reassessment:
- Dose escalation without clear clinical justification
- Sessions being used for escape from emotional distress rather than as structured therapeutic events
- Increased urgency or craving around session timing
- Declining benefit at stable doses
Ongoing honest communication with your provider is the best protection against inappropriate use patterns developing.
Key Takeaways
- Acute treatment (loading phase) typically involves 2 to 3 sessions per week for 4 to 6 weeks.
- Maintenance treatment involves progressively lower frequency (weekly, biweekly, monthly) once response is established.
- Maintenance doses are often lower than acute doses.
- Response durability is enhanced by concurrent psychotherapy, antidepressants, and lifestyle factors.
- Long-term maintenance is appropriate for some patients; others achieve lasting remission and successfully discontinue.
- Distinguish appropriate maintenance from dependency through honest provider-patient communication and outcome monitoring.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
- WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches
Share